The FDA says its safety review of mifepristone will not be made public until later, prompting criticism from Republican lawmakers who want answers on the abortion pill.
Follow the storyGOP8 stories
01Summary
- 01The Food and Drug Administration has said its safety review of mifepristone will not be public until later.
- 02Congressional Republicans have raised pointed questions about the FDA’s handling of the review.
- 03The review concerns mifepristone, an abortion drug.
- 04The story does not say when the review will be completed or released.
02Why it matters
The FDA’s handling of mifepristone affects abortion access and is likely to draw political pressure from Congress. Any change in the agency’s review could influence how the drug is regulated.
Pulse AIAsk about this story
Answers are generated by AI from the story summary; they are not investment, health or legal advice.
